(ALAFY) Afyren SAS - Ratings and Ratios

Afyren SAS (PA:ALAFY) is a French specialty chemicals company pioneering the production of bio-based ingredients to replace petroleum-derived alternatives. Utilizing proprietary fermentation technology, the company converts non-food biomass into high-value organic acids, including acetic, propionic, butyric, isobutyric, isovaleric, valeric, and caproic acids. These products serve diverse markets such as human and animal nutrition, lubricants, flavors and fragrances, and life sciences and materials sciences. Founded in 2012 and headquartered in Clermont-Ferrand, France, Afyren operates at the intersection of sustainability and chemistry, addressing growing demand for eco-friendly alternatives in various industries. Web URL: https://afyren.com

The companys organic acids are critical building blocks in numerous applications, from food additives and animal feed to pharmaceutical intermediates and biodegradable materials. Afyrens focus on non-food biomass ensures its processes do not compete with agricultural markets, aligning with global sustainability goals. Its innovative approach has positioned the company as a key player in the bioeconomy, with potential for further expansion into emerging markets such as bioplastics and green chemicals.

3-Month Forecast:

Based on and , Afyren SAS (PA:ALAFY) is expected to face near-term headwinds. The stock price is currently below its SMA 20 (1.82) and SMA 50 (1.89), indicating bearish momentum. The SMA 200 (2.34) suggests longer-term downward pressure. With an ATR of 0.13, volatility is expected to remain low, limiting near-term price swings. From a perspective, the high P/S ratio of 15.96 reflects investor confidence in growth potential, but the negative RoE (-30.21) and lack of profitability (P/E: 0.00) raise concerns about scalability and execution. The companys market cap of 44.51M EUR and P/B ratio of 0.77 indicate moderate valuation relative to book value. Overall, the stock is likely to remain under pressure in the next quarter as investors await clearer signs of profitability and revenue growth.